Goksal Oney

#MS in Marriage and Family Therapy @Northwestern University #MSc in Health Psychology #CBT Therapist #Psychology Teacher 👩🏻‍🏫 #Cypriot 🇨🇾 ✌🏼

[BiotechTV @BiotechTV]

𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: @DispatchBio is trying to solve the solid tumor challenge for CAR-T by designing bespoke antigens that light up tumors. At ASGCT, they also have data on a unique cytokine for armoring CARs. #ASGCT2026

Full video: https://t.co/tyT1vmPSVH

[Dispatch Bio @DispatchBio]

We were honored to receive the Emerging Company of the Year Award at the @LifeSciencesPA 2026 Annual Dinner & Showcase.

This recognition reflects our team’s persistence and determination to advance new approaches designed to overcome the challenges of treating solid tumors.

[Goksal Oney @9oksal]

https://t.co/4tZnKfwobu via @fredhutch

[Sabah Öney @sabahoney]

This is cool, thanks for the recognition!

2026 is a consequential year for Dispatch and for cancer patients.

[Goksal Oney @9oksal]

NextGen: Class of 2026 - BioSpace https://t.co/G8fYucNRd4

[Sabah Öney @sabahoney]

Getting our first product to the patients who need it the most - and doing it fast and efficiently.

At @DispatchBio - we designed DISP-10 to not only address some of the largest unmet medical needs but also, go from first patient dosed to approved product in record time.

[Sabah Öney @sabahoney]

Congratulations @seanmehra and the rest of the HealthTap team. Good for both companies and great for patients!

[Goksal Oney @9oksal]

Sabah Öney, MBA ’12 | Stanford Graduate School of Business https://t.co/8ObZeARTvr

[Dispatch Bio @DispatchBio]

We’re honored to be named a 2025 #Endpoints11 company by @endpts. This award underscores the importance of our mission to help create a world where all cancer patients can be cured.Thank you to all who are working to bring this vision to life.

[Dispatch Bio @DispatchBio]

Hear from our CEO, @sabahoney, on The Long Run podcast: “CAR-T Cells Against Solid Tumors.”

He shares more on Dispatch’s beginning, our unique #immunotherapy approach, how we aim to make an impact for patients with solid tumors and more.

Listen below.

[Dispatch Bio @DispatchBio]

With solid tumors representing ~90% of cancers, Dispatch Bio is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform to help create a world where all #cancer patients can be cured. Learn more: https://t.co/Ps48IbX2Cg

[Goksal Oney @9oksal]

Immunotherapy for Solid Tumors: Dispatch Biotherapeutics https://t.co/6A1pye0GHr

[Goksal Oney @9oksal]

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach - https://t.co/nXmN2KpvXY

[Goksal Oney @9oksal]

Dispatch Bio has VC backing for 'universal cancer treatment' - San Francisco Business Times https://t.co/9Ymq2hGY2f via @SFBusinessTimes

[Goksal Oney @9oksal]

Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy | BioPharma Dive https://t.co/Mrszh6O6jk

[Goksal Oney @9oksal]

Parker Institute, ARCH unveil CAR-T biotech with $216M to crack solid tumors https://t.co/4WTLXKCp6p

[Goksal Oney @9oksal]

Cancer biotech Dispatch unveils with $216M and CAR-T pioneer Carl June as cofounder https://t.co/NWJBr0cEat

[Goksal Oney @9oksal]

Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach https://t.co/Y5DXXvhdwe via @statnews

[Goksal Oney @9oksal]

@sabahoney 💯

[Elliot Hershberg @ElliotHershberg]

Awesome take by Carl June at the FDA's cell & gene therapy roundtable.

Before considering trade regulations, we should look in the mirror and see what we can improve!

There probably is a place for IITs in the US system.